Transgene Stock

Transgene CROIC

The Cash Return on Invested Capital (CROIC) of Transgene (TNG.PA) as of Aug 17, 2026 is -104.63 %. In the previous year, Cash Return on Invested Capital (CROIC) was -113.78 % — a change of -8.04% (higher).

CROIC

-104.63 %

YoY

-8.04%

Last updated:

Cash Return on Invested Capital (CROIC) of Transgene is 2026 -104.63 % . Cash Return on Invested Capital (CROIC) of Transgene was 2025 -113.78 % . It decreases by -8.04% higher compared to the previous year.
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Cash Return on Invested Capital (CROIC) of Transgene is -104.63 % in 2026.

Cash Return on Invested Capital (CROIC) of Transgene changed from -113.78 % to -104.63 %, representing a -8.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Transgene since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

Profitability — Transgene

All Key Metrics — Transgene